Methods of treating cancer in a patient by administering anti-folate-receptor-1 (FOLR1) antibodies
The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
1. A method of treating cancer in a patient, said method comprising:
(a) determining a folate receptor 1 (FOLR1) expression score from a detection of FOLR1 expression in a cancerous sample obtained from the patient, wherein the detection is performed using a detection antibody or antigen-binding fragment thereof that specifically binds to an epitope of FOLR1 comprising an N-glycosylated amino acid, wherein said detection antibody or fragment thereof competitively inhibits binding to FOLR1 of an antibody comprising a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:27 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:28; and
(b) administering an effective amount of an active agent comprising an anti-FOLR1 antibody or antigen binding fragment thereof to the patient if the score indicates the patient will benefit from administration of the active agent.
2. A method of treating cancer in a patient, said method comprising:
(a) submitting a cancerous sample taken from a patient having cancer for determining a folate receptor 1 (FOLR1) expression score from a detection of FOLR1 expression using a detection antibody or antigen-binding fragment thereof that specifically binds to an epitope of FOLR1 comprising an N-glycosylated amino acid, wherein said detection antibody or fragment thereof competitively inhibits binding to FOLR1 of an antibody comprising a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:27 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:28; and
(b) administering an effective amount of an active agent comprising an anti-FOLR1 antibody or antigen binding fragment thereof to the patient if the score indicates the patient will benefit from administration of the active agent.
3. A method of treating cancer in a patient with an active agent comprising an anti-folate receptor 1 (FOLR1) antibody or antigen-binding fragment thereof, said method comprising administering an effective amount of the active agent to the patient having cancer, wherein increased expression of FOLR1 has been detected in a cancerous sample from the patient using a detection antibody or antigen-binding fragment thereof that specifically binds to an epitope of FOLR1 comprising an N-glycosylated amino acid, wherein said detection antibody or fragment thereof competitively inhibits binding to FOLR1 of an antibody comprising a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:27 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:28.
4. The method of claim 3 , wherein said cancerous sample is a bodily fluid, cell, or tissue sample.
5. The method of claim 4 , wherein said bodily fluid is blood, ascites, urine, plasma, serum, or peripheral blood.
6. The method of claim 3 , wherein the FOLR1 is shed FOLR1.
7. The method of claim 3 , wherein the detecting is by enzyme linked immunosorbent assay (ELISA).
8. The method of claim 3 , wherein the detecting is by immunohistochemistry (IHC).
9. The method of claim 8 , wherein a FOLR1 score of at least 2 in 25% or greater of the cells identifies the cancer as likely to respond to an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof or indicates that the patient will benefit from administration of an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof.
10. The method of claim 8 , wherein a FOLR1 score of at least 3 in 25% or greater of the cells identifies the cancer as likely to respond to an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof or indicates that the patient will benefit from administration of an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof.
11. The method of claim 8 , wherein a FOLR1 score of at least 2 in 25% to 75% of the cells identifies the cancer as likely to respond to an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof or indicates that the patient will benefit from administration of an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof.
12. The method of claim 8 , wherein a FOLR1 score of at least 2 in greater than 75% of the cells identifies the cancer as likely to respond to an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof or indicates that the patient will benefit from administration of an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof.
13. The method of claim 8 , wherein a FOLR1 score of at least 3 in 25% to 75% of the cells identifies the cancer as likely to respond to an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof or indicates that the patient will benefit from administration of an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof.
14. The method of claim 8 , wherein a FOLR1 score of at least 3 in greater than 75% of the cells identifies the cancer as likely to respond to an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof or indicates that the patient will benefit from administration of an active agent comprising an anti-FOLR1 antibody or antigen-binding fragment thereof.
15. The method of claim 3 , wherein said cancer is selected from the group consisting of ovarian, brain, breast, uterine, endometrial, pancreatic, renal, lung cancer, and cancer of the peritoneum.
16. The method of claim 15 , wherein the ovarian cancer is epithelial ovarian cancer.
17. The method of claim 16 , wherein the cancer is platinum resistant, relapsed, or refractory.
18. The method of claim 3 , wherein the antibody or antigen-binding fragment thereof of the active agent comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:45 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:47.
19. The method of claim 18 , wherein the active agent is an antibody maytansinoid conjugate comprising the maytansinoid N(2′)-deacetyl-N2′-(4-mercapto-4-methyl-1-oxopentyl)-maytansine (DM4) and the N-succinimidyl 4-(2-pyridyldithio)-2-sulfobutanoate (sulfo-SPDB) linker.
20. The method of claim 3 , wherein the detection antibody or antigen-binding fragment thereof comprises the VH CDR1-3 and VL CDR1-3 polypeptide sequences selected from the group consisting of:
(a) SEQ ID NOs:3-8, respectively;
(b) SEQ ID NOs:9-14, respectively;
(c) SEQ ID NOs:15-20, respectively;
(d) SEQ ID NOs:21-26, respectively;
(e) SEQ ID NOs: 3-5 and SEQ ID NOs: 59, 7, and 8, respectively;
(f) SEQ ID NOs: 3, 60, and 5 and SEQ ID NOs: 6-8, respectively;
(g) SEQ ID NOs: 3, 61, and 5 and SEQ ID NOs: 6-8, respectively;
(h) SEQ ID NOs: 3, 60, and 5 and SEQ ID NOs: 59, 7, and 8, respectively; and
(i) SEQ ID NOs: 3, 61, and 5 and SEQ ID NOs: 59, 7, and 8, respectively.
21. The method of claim 3 , wherein the detection antibody or antigen-binding fragment thereof is chimeric or humanized.
22. The method of claim 3 , wherein the detection antibody or antigen-binding fragment thereof is a full-length antibody.
23. The method of claim 3 , wherein the detection antibody or antigen-binding fragment thereof is an antigen-binding fragment.
24. The method of claim 3 , wherein the detection antibody or antigen-binding fragment thereof binds to a human folate receptor 1 with a Kd of about 0.5 to about 10 nM.
25. The method of claim 3 , wherein the detection antibody or antigen-binding fragment thereof further comprises a detectable label.
26. The method of claim 25 , wherein said detectable label is selected from the group consisting of immunofluorescent label, chemiluminescent label, phosphorescent label, enzyme label, radiolabel, luminophore, avidin/biotin, colloidal gold particles, colored particles, and magnetic particles.
27. The method of claim 26 , wherein said detectable label is selected from the group consisting of biotin, digoxigenin, fluorescein, tritium, and rhodamine.
28. The method of claim 3 , wherein the detection antibody or antigen-binding fragment thereof comprises:
i. a heavy chain variable region (VH) comprising the amino acid sequence of the polypeptide of SEQ ID NO:27 and a light chain variable region (VL) comprising the amino acid sequence the polypeptide of SEQ ID NO:28;
ii. a heavy chain variable region (VH) comprising the amino acid sequence of the polypeptide of SEQ ID NO:29 and a light chain variable region (VL) comprising the amino acid sequence the polypeptide of SEQ ID NO:30;
iii. a heavy chain variable region (VH) comprising the amino acid sequence of the polypeptide of SEQ ID NO:31 and a light chain variable region (VL) comprising the amino acid sequence the polypeptide of SEQ ID NO:32;
iv. a heavy chain variable region (VH) comprising the amino acid sequence of the polypeptide of SEQ ID NO:62 and a light chain variable region (VL) comprising the amino acid sequence the polypeptide of SEQ ID NO:63 or SEQ ID NO:64; or
v. a heavy chain variable region (VH) comprising the amino acid sequence of the polypeptide of SEQ ID NO:65 and a light chain variable region (VL) comprising the amino acid sequence the polypeptide of SEQ ID NO:66 or SEQ ID NO:67.
29. The method of claim 3 , wherein the detection antibody or antigen-binding fragment thereof comprises:
a heavy chain comprising the amino acid sequence of SEQ ID NO:33 and a light chain comprising the amino acid sequence of SEQ ID NO:34;
a heavy chain comprising the amino acid sequence of SEQ ID NO:35 and a light chain comprising the amino acid sequence of SEQ ID NO:36; or
a heavy chain comprising the amino acid sequence of SEQ ID NO:37 and a light chain comprising the amino acid sequence of SEQ ID NO:38.